Clinical significance of HCV core region, to antiviral therapy and clinicopatological features.

• Project/Area Number: 21590866
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Gastroenterology
• Research Institution: Okinaka Memorial Institute for Medical Research
• Principal Investigator: AKUTA Norio 財団法人冲中記念成人病研究所, 研究員 (20469638)
• Project Period (FY): 2009 – 2011
• Project Status: Completed (Fiscal Year 2011)
• Budget Amount: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000); Fiscal Year 2011: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2010: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2009: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
• Keywords: 肝臓学 / HCV / Coreアミノ酸置換 / Peginterferon / Ribavirin / 肝発癌 / 脂質代謝 / NS5A-ISDR / 糖代謝 / インスリン抵抗性 / HOMA-IR

Research Abstract

Clinical significance of HCV core region, to antiviral therapy and clinicopatological features, was investigated. Substitutions of amino acid 70 and 91 of HCV genotype 1b could predict the response to peginterferon/ribavirin combination therapy and new therapy with Telaprevir. Furthermore, those also affected clinical outcome, including hepatocarcinogenesis, glucose metabolism, and lipid metabolism.

Research Products

• [Journal Article] Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy (2012)
  • Author(s): Akuta N, Kumada H(他13名, 1番目)
  • Journal Title: Intervirology Volume: 55 Pages: 231-41
  • Peer Reviewed
• [Journal Article] Amino Acid Substitution in HCV Core/NS5A Region and Genetic Variati on Near IL28B Gene Affect Treatment Efficacy to Interferon plus Ribavirin Combination Therapy (2012)
  • Author(s): Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H
  • Journal Title: Intervirology Volume: 55 Issue: 3 Pages: 231-41
  • DOI: 10.1159/000328327
  • Peer Reviewed
• [Journal Article] Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy (2011)
  • Author(s): Akuta N, Kumada H(他11名, 1番目)
  • Journal Title: J Med Virol Volume: 83 Pages: 1016-1022
  • Peer Reviewed
• [Journal Article] Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy (2011)
  • Author(s): 芥田憲夫
  • Journal Title: Journal of Medical Virology Volume: VOL.83 Issue: 6 Pages: 1016-1022
  • DOI: 10.1002/jmv.22094
  • Peer Reviewed
• [Journal Article] Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin (2010)
  • Author(s): Akuta N, Kumada H(他14名, 1番目)
  • Journal Title: Hepatology Volume: 52 Pages: 412-429
  • Peer Reviewed
• [Journal Article] Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin (2010)
  • Author(s): Akuta N, Kumada H(他12名, 1番目)
  • Journal Title: J Med Virol Volume: 82 Pages: 575-582
  • Peer Reviewed
• [Journal Article] Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. (2010)
  • Author(s): 芥田憲夫
  • Journal Title: Hepatology Volume: VOL.52 Pages: 412-429
  • Peer Reviewed
• [Journal Article] Amino acid substitutions in the hepatitis C virus core region of genotype]b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin. (2010)
  • Author(s): 芥田憲夫
  • Journal Title: Journal of Medical Virology Volume: VOL.82 Pages: 575-582
  • Peer Reviewed
• [Journal Article] Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus (2009)
  • Author(s): Akuta N, Kumada H(他12名, 1番目)
  • Journal Title: J Med Virol Volume: 81 Pages: 1032-1039
  • Peer Reviewed
• [Journal Article] A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan : amino acid substitutions in HCV core region as predictor of sustained virological response (2009)
  • Author(s): Akuta N, Kumada H(他12名, 1番目)
  • Journal Title: J Med Virol Volume: 81 Pages: 452-458
  • Peer Reviewed
• [Journal Article] Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy (2009)
  • Author(s): Akuta N, Kumada H(他12名, 1番目)
  • Journal Title: Intervirology Volume: 52 Pages: 301-309
  • Peer Reviewed
• [Journal Article] Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus (2009)
  • Author(s): 芥田憲夫
  • Journal Title: Journal of Medical Virology VOL.81 Pages: 1032-1039
  • Peer Reviewed
• [Journal Article] A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan : amino acid substitutions in HCV core region as predictor of sustained virological response (2009)
  • Author(s): 芥田憲夫
  • Journal Title: Journal of Medical Virology VOL.81 Pages: 452-458
  • Peer Reviewed
• [Journal Article] Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy (2009)
  • Author(s): 芥田憲夫
  • Journal Title: Intervirology VOL.52 Pages: 301-309
  • Peer Reviewed
• [Presentation] Amino acid substitution in the hepatitis C virus core region of genotype 1b are the important predictor of telaprevir with peginterferon plus ribavirin, and hepatocarcinogenesis (2011)
  • Author(s): 芥田憲夫
  • Organizer: The 62th annual meeting of the American association for the study of liver disease
  • Place of Presentation: CA(USA)
  • Year and Date: 2011-11-06
• [Presentation] Amino acid substitution in the hepatitis C virus core region of genotype 1b are the important predictor of telaprevir with peginterferon plus ribavirin, and hepatocarcinogenesis (2011)
  • Author(s): 芥田憲夫
  • Organizer: The 62th annual meeting of the American association for the study of liver disease, 2011
  • Place of Presentation: CA (USA)
  • Year and Date: 2011-11-06
• [Presentation] C型肝炎の治療抵抗性と肝発癌に影響するウイルス・宿主要因の検討 (2011)
  • Author(s): 芥田憲夫
  • Organizer: 第15回日本肝臓学会大会
  • Place of Presentation: 福岡サンパレス(東京都)
  • Year and Date: 2011-10-20
• [Presentation] HCV coreアミノ酸置換が肝発癌・代謝要因に及ぼす影響 (2011)
  • Author(s): 芥田憲夫
  • Organizer: 第47回日本肝臓学会総会
  • Place of Presentation: ホテルグランパシフィックLE DAIBA(東京都)
  • Year and Date: 2011-06-02
• [Presentation] 新規抗HCV療法を含めた難治要因の検討と代謝要因への影響 (2011)
  • Author(s): 芥田憲夫
  • Organizer: 第97回日本消化器病学会総会
  • Place of Presentation: 京王プラザホテル(東京都)
  • Year and Date: 2011-05-13
• [Presentation] Amino acid substitutions in HCV core region of genotype 1b are the important viral predictors of treatment resistance and hepatocarcinogenesis (2010)
  • Author(s): 芥田憲夫
  • Organizer: 7th APASL Single Topic Conference"Hepatitis C Virus"
  • Place of Presentation: 幕張メッセ(千葉県)
  • Year and Date: 2010-12-17
• [Presentation] Amino acid substitutions in HCV core region of genotype Ib are the important viral predictors of treatment resistance and hepatocarcinogenesis. (2010)
  • Author(s): 芥田憲夫
  • Organizer: 7th APASL Single Topic Conference Hepatitis C Virus
  • Place of Presentation: 幕張メッセ(千葉県)
  • Year and Date: 2010-12-17
• [Presentation] Coreアミノ酸置換とIL28B遺伝子多型のPEG-IFN/RBV/Telaprevir併用療法における有用性 (2010)
  • Author(s): 芥田憲夫
  • Organizer: 第38回日本肝臓学会東部会
  • Place of Presentation: 京王プラザホテル(東京都)
  • Year and Date: 2010-12-02
• [Presentation] Coreアミノ酸置換とIL28B遺伝子多型のPEG-IFN/SBV/Telaprevir併用療法における有用性 (2010)
  • Author(s): 芥田憲夫
  • Organizer: 第38回日本肝臓学会東部会
  • Place of Presentation: 京王プラザホテル(東京都)
  • Year and Date: 2010-12-02
• [Presentation] PEG-IFN/RBV/Telaprevir併用療法におけるCore aa70置換とIL28B遺伝子多型の有用性 (2010)
  • Author(s): 芥田憲夫
  • Organizer: 第14回日本肝臓学会大会
  • Place of Presentation: パシフィコ横浜(神奈川県)
  • Year and Date: 2010-10-14
• [Presentation] HCV coreアミノ酸置換の新規抗HCV療法・肝発癌に及ぼす影響 (2010)
  • Author(s): 芥田憲夫
  • Organizer: 第96回日本消化器病学会総会
  • Place of Presentation: 新潟県民会館(新潟県)
  • Year and Date: 2010-04-24
• [Presentation] Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of treatment resistance, insulin resistance, and hepatocarcinogenesis (2009)
  • Author(s): 芥田憲夫
  • Organizer: The 60th annual meeting of the American association for the study of liver disease
  • Place of Presentation: BOSTON HYNES CONVENTION CENTER(USA)
  • Year and Date: 2009-11-01
• [Presentation] 抗ウイルス療法・肝病態におけるHCV-1b core aa70/91の意義 (2009)
  • Author(s): 芥田憲夫
  • Organizer: 第45回日本肝臓学会総会
  • Place of Presentation: 神戸ポートピアホテル(兵庫県)
  • Year and Date: 2009-06-04
• [Patent(Industrial Property Rights)] B型肝炎ウイルス量が低下する可能性を予測する方法 (2007)
  • Inventor(s): 熊田博光・芥田憲夫
  • Industrial Property Rights Holder: 熊田博光・芥田憲夫
  • Industrial Property Number: 2007-340261
  • Filing Date: 2007-12-28
• [Patent(Industrial Property Rights)] B型肝炎ウイルス量が低下する可能性を予測する方法 (2007)
  • Inventor(s): 熊田博光, 芥田憲夫
  • Industrial Property Rights Holder: 熊田博光, 芥田憲夫
  • Industrial Property Number: 2007-340261
  • Filing Date: 2007-12-28
• [Patent(Industrial Property Rights)] C型肝炎に対するインターフェロン/リバビリン併用療法の有効性 (2005)
  • Inventor(s): 熊田博光・芥田憲夫
  • Industrial Property Rights Holder: 熊田博光・芥田憲夫
  • Patent Publication Number: 2007-043985
  • Filing Date: 2005-08-11
• [Patent(Industrial Property Rights)] C型肝炎に対するインターフェロン/リバビリン併用療法の有効性 (2005)
  • Inventor(s): 熊田博光, 芥田憲夫
  • Industrial Property Rights Holder: 熊田博光, 芥田憲夫
  • Patent Publication Number: 2007-043985
  • Filing Date: 2005-08-11